- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04303403
Study of Trametinib and Ruxolitinib in Colorectal Cancer and Pancreatic Adenocarcinoma
Phase Ib Study Evaluating Safety and Tolerability of Combination Trametinib and Ruxolitinib in Patients With Advanced RAS Mutant Colorectal Cancer and Pancreatic Adenocarcinoma
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: David Tai, MD
- Phone Number: +65 6436 8000
- Email: david.tai.w.m@singhealth.com.sg
Study Locations
-
-
-
Singapore, Singapore, 169610
- Recruiting
- National Cancer Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients (male or female) ≥ 21.
- Patients with histological diagnosis of RAS mutant advanced colorectal and pancreatic adenocarcinoma having received at least 1 prior line of systemic therapy. Pancreatic cancer patients with KRAS mutation detected on plasma profiling having received at least 1 prior line of systemic therapy.
- Patients must have at least one measurable lesion according to Response Evaluation Criteria in Solid Tumours (RECIST) criteria version 1.1.
- Life expectancy of at least 3 months.
- Written informed consent that is consistent with ICH-GCP guidelines.
- Eastern Cooperative Oncology Group (ECOG) performance score ≤ 2.
Have adequate organ and hematologic function, as determined by:
- Absolute neutrophil count (ANC) ≥ 1,500/μl.
- Platelets ≥ 100,000/μl.
- Haemoglobin ≥ 9g/dL.
- Aspartate Amino Transferase (AST)/ Alanine Amino Transferase (ALT) ≤ 2.5 x upper limit of normal (ULN ≤ 5 x ULN is acceptable if liver metastases are present).
- Total bilirubin ≤1.5 x ULN (< 3 ULN for patients with Gilbert syndrome).
- Creatinine clearance ≥ 60ml/min.
- Prothrombin time and activated partial thromboplastin time ≤ 1.5 x upper limit of normal (ULN) per institutional laboratory normal range.
- Ejection fraction ≥ 50% with no symptoms attributable to heart failure.
- Have normal QT interval on screening electrocardiogram (ECG) evaluation, defined as QT interval corrected (Fridericia) (QTcF) of ≤450 ms in males or ≤470 ms in females.
- For female patients of childbearing potential, a negative pregnancy test must be documented prior to enrolment.
- Female and male patients who are fertile must agree to use a highly effective form of contraception with their sexual partners throughout study participation.
- Have the willingness and ability to comply with scheduled visits and study procedures.
Exclusion Criteria:
- Received cytotoxic chemotherapy, investigational agents, or radiation within 14 days of study drug commencement, or 5 half-lives, whichever is shorter, and with recovery of clinically significant toxicities from that therapy.
- Received monoclonal antibodies or had surgery within 30 days of the first dose of study drug.
- Have been diagnosed with another primary malignancy within the past 3 years of study drug commencement (except for adequately treated non-melanoma skin cancer, cervical cancer in situ, or prostate cancer).
- Have CNS metastases that are symptomatic, neurologically unstable, or requiring an increasing dose of corticosteroids.
- Have meningeal involvement or spinal cord compression.
Have significant, uncontrolled, or active cardiovascular disease, specifically including, but not restricted to:
- Myocardial infarction (MI) within 6 months prior to the first dose.
- Unstable angina within 6 months prior to first dose.
- History of congestive heart failure (CHF).
- History of clinically significant atrial arrhythmia.
- Any history of ventricular arrhythmia.
- Cerebrovascular accident or transient ischemic attack within 6 months prior to first dose.
- Have history or the presence of pulmonary interstitial disease or drug related pneumonitis.
- Have an ongoing or active infection.
- Patients with active HBV and HCV are excluded unless they are undergoing treatment for HBV and HCV.
- Have a history of or active significant gastrointestinal (GI) bleeding within 3 months of the first dose.
- Patients who are on immunosuppressive therapy.
- Patients who have retinal vein occlusion and retinal pigment epithelial detachment.
- On medications which are potent and moderate inhibitor and inducers of CYP3A4.
- Patients with moderate to severe hepatic impairment (Child Pugh B and C).
- Patients with history of severe allergic skin reactions or current skin conditions.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose Escalation and Expansion
Dose Escalation: Trametinib 2mg daily monotherapy for 14 days. Followed by combination oral trametinb (2mg starting dose) daily and oral ruxolitinib (5mg starting dose) twice daily at assigned doses. Dose Expansion: Combination oral trametinb daily and oral ruxolitinib twice daily at the maximum tolerated dose (MTD) established at the Dose Escalation phase. A cycle of therapy will comprise of 28 days of combination trametinib and ruxolitinib treatment. |
Taken orally once daily
Other Names:
Taken orally twice daily
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Tolerated Dose
Time Frame: 28 days (1 cycle)
|
Highest dose level at which less than one-third of the patients in the dose level experienced dose limiting toxicities (DLTs) during the first cycle of treatment
|
28 days (1 cycle)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency and severity of treatment-emergent Adverse Events and Serious Adverse Events
Time Frame: From time of first study drug administration until 30 days after last dose of study drug
|
To assess the safety of the drug combination.
During the dose escalation phase, this includes the incidences of dose limiting toxicities during the first 2 cycles of treatment.
|
From time of first study drug administration until 30 days after last dose of study drug
|
Changes between baseline and post-baseline hematology laboratory parameters during treatment - Haemoglobin
Time Frame: From time of first study drug administration until 30 days after last dose of study drug
|
Unit of measure: g/dL.
To assess the safety of the drug combination
|
From time of first study drug administration until 30 days after last dose of study drug
|
Changes between baseline and post-baseline hematology laboratory parameters during treatment - White blood count, Platelets, Absolute neutrophil count
Time Frame: From time of first study drug administration until 30 days after last dose of study drug
|
Unit of measure: x 10^9/L.
To assess the safety of the drug combination.
|
From time of first study drug administration until 30 days after last dose of study drug
|
Changes between baseline and post-baseline hematology laboratory parameters during treatment - Neutrophils
Time Frame: From time of first study drug administration until 30 days after last dose of study drug
|
Unit of measure: Percentage component of white blood cells.
To assess the safety of the drug combination.
|
From time of first study drug administration until 30 days after last dose of study drug
|
Changes between baseline and post-baseline biochemistry laboratory parameters during treatment - Urea, Sodium, Potassium, Chloride, Bicarbonate, Glucose, Magnesium, Calcium, Phosphate, Total cholesterol, High and low density lipoprotein, Triglycerides
Time Frame: From time of first study drug administration until 30 days after last dose of study drug
|
Unit of measure: mmol/L.
To assess the safety of the drug combination
|
From time of first study drug administration until 30 days after last dose of study drug
|
Changes between baseline and post-baseline biochemistry laboratory parameters during treatment - Uric acid, Creatinine, Total bilirubin
Time Frame: From time of first study drug administration until 30 days after last dose of study drug
|
Unit of measure: umol/L.
To assess the safety of the drug combination
|
From time of first study drug administration until 30 days after last dose of study drug
|
Changes between baseline and post-baseline biochemistry laboratory parameters during treatment - Total protein, Albumin
Time Frame: From time of first study drug administration until 30 days after last dose of study drug
|
Unit of measure: g/L.
To assess the safety of the drug combination
|
From time of first study drug administration until 30 days after last dose of study drug
|
Changes between baseline and post-baseline biochemistry laboratory parameters during treatment - Alkaline phosphatase, Alanine transaminase, Aspartate transaminase, Lactate dehydrogenase, Beta-human chorionic gonadotrophin
Time Frame: From time of first study drug administration until 30 days after last dose of study drug
|
Unit of measure: U/L.
To assess the safety of the drug combination
|
From time of first study drug administration until 30 days after last dose of study drug
|
Frequency of dose interruptions
Time Frame: From time of first study drug administration until 30 days after last dose of study drug
|
To assess the tolerability of the drug combination.
|
From time of first study drug administration until 30 days after last dose of study drug
|
Frequency of dose reductions
Time Frame: From time of first study drug administration until 30 days after last dose of study drug
|
To assess the tolerability of the drug combination
|
From time of first study drug administration until 30 days after last dose of study drug
|
Pharmacokinetics (PK): Trough concentrations of trametinb
Time Frame: From cycle 1-6 of study (each cycle is 28 days)
|
Trough concentrations of trametinb at different cycles of combination treatment with ruxolitinib
|
From cycle 1-6 of study (each cycle is 28 days)
|
Tumour Markers: CEA and CA 19-9 in blood samples
Time Frame: From cycle 1 up to last cycle of treatment (each cycle is 28 days)
|
Changes from baseline tumour markers (CEA and CA 19-9) in blood samples
|
From cycle 1 up to last cycle of treatment (each cycle is 28 days)
|
Overall Response Rate
Time Frame: From time of first study drug administration until first occurrence of disease progression, up to 2 years
|
The best overall response is the best response recorded from the start of the treatment until disease progression (PD)/ recurrence (taking as reference for PD the smallest measurements recorded since the treatment started).
|
From time of first study drug administration until first occurrence of disease progression, up to 2 years
|
Disease Control Rate
Time Frame: From time of first study drug administration until best overall response, first occurence of disease progression, up to 2 years
|
Percentage of patients who have achieved complete response, partial response and stable disease in accordance to RECIST 1.1.
|
From time of first study drug administration until best overall response, first occurence of disease progression, up to 2 years
|
Progression Free Survival
Time Frame: From time of first study drug administration until first occurence of disease progression, or death from any cause, up to 2 years
|
Time elapsed between treatment initiation and tumour progression or death from any cause, with censoring of patients who are lost to follow-up.
|
From time of first study drug administration until first occurence of disease progression, or death from any cause, up to 2 years
|
Overall Survival
Time Frame: From time of first study drug administration to death from any cause, up to 2 years
|
Time elapsed between treatment initiation and death from any cause, with censoring of patients who are lost to follow-up.
|
From time of first study drug administration to death from any cause, up to 2 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: David Tai, MD, National Cancer Centre, Singapore
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Adenocarcinoma
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Trametinib
Other Study ID Numbers
- CTMT212XSG01T
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colorectal Cancer
-
University of California, San FranciscoCompletedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRectal Cancer | Colon Cancer | Cancer Survivor | Colorectal Adenocarcinoma | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage... and other conditionsUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
M.D. Anderson Cancer CenterRecruitingColorectal Adenocarcinoma | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage... and other conditionsUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedCancer Survivor | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage IIA Colorectal Cancer AJCC v8 | Stage IIB Colorectal... and other conditionsUnited States
-
City of Hope Medical CenterRecruitingColorectal Neoplasms | Colorectal Cancer | Colorectal Adenocarcinoma | Colorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Neoplasms Malignant | Colorectal Cancer Stage IUnited States, Japan, Italy, Spain
-
Sidney Kimmel Cancer Center at Thomas Jefferson...United States Department of DefenseActive, not recruitingColorectal Adenoma | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage 0 Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage IIA Colorectal... and other conditionsUnited States
-
University of Roma La SapienzaCompletedColorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Cancer Stage 0 | Colorectal Cancer Stage IItaly
-
University of Southern CaliforniaNational Cancer Institute (NCI); AmgenTerminatedStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Colorectal Adenocarcinoma | RAS Wild Type | Stage III Colorectal Cancer AJCC v7 | Stage IIIA Colorectal Cancer AJCC v7 | Stage IIIB Colorectal Cancer AJCC v7 | Stage IIIC Colorectal Cancer...United States
Clinical Trials on Trametinib
-
Melanoma Institute AustraliaNovartisRecruiting
-
Memorial Sloan Kettering Cancer CenterCompletedNon Small Cell Lung Cancer | KRAS Gene MutationUnited States
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompleted
-
Stanford UniversityBoston Children's HospitalRecruitingArterial Disease | Venous MalformationUnited States
-
The Netherlands Cancer InstituteGlaxoSmithKlineUnknown
-
Shanghai Henlius BiotechRecruiting
-
University Health Network, TorontoNot yet recruitingArteriovenous Malformations
-
Dana-Farber Cancer InstituteNovartis; National Comprehensive Cancer NetworkTerminated
-
Universitair Ziekenhuis BrusselCompleted